140 related articles for article (PubMed ID: 36088563)
1. Primary central nervous system malignant lymphoma in a patient with rheumatoid arthritis receiving tocilizumab: illustrative case.
Ohno M; Kuramitsu S; Iwakoshi A; Yamaguchi J; Ohka F; Saito R
J Neurosurg Case Lessons; 2022 Aug; 4(6):. PubMed ID: 36088563
[TBL] [Abstract][Full Text] [Related]
2. Primary central nervous system malignant lymphoma in a patient with rheumatoid arthritis receiving low-dose methotrexate treatment.
Fukushima M; Katayama Y; Yokose N; Kura Y; Sawada U; Kotani A; Yoshino A
Br J Neurosurg; 2013 Dec; 27(6):824-6. PubMed ID: 23705580
[TBL] [Abstract][Full Text] [Related]
3. Methotrexate-associated primary hepatic lymphoma and cranial neuropathy in a patient with rheumatoid arthritis: A case report with clinical follow-up over a 7-year period.
Park JE; Lee KM; Choi HY; Ahn SE; You MW
Medicine (Baltimore); 2019 Apr; 98(17):e14997. PubMed ID: 31027052
[TBL] [Abstract][Full Text] [Related]
4. Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease-modifying antirheumatic drugs and after the failure of conventional disease-modifying antirheumatic drugs only: systematic review and economic evaluation.
Stevenson M; Archer R; Tosh J; Simpson E; Everson-Hock E; Stevens J; Hernandez-Alava M; Paisley S; Dickinson K; Scott D; Young A; Wailoo A
Health Technol Assess; 2016 Apr; 20(35):1-610. PubMed ID: 27140438
[TBL] [Abstract][Full Text] [Related]
5. Malignant Neoplasms in Patients With Rheumatoid Arthritis Treated With Tumor Necrosis Factor Inhibitors, Tocilizumab, Abatacept, or Rituximab in Clinical Practice: A Nationwide Cohort Study From Sweden.
Wadström H; Frisell T; Askling J;
JAMA Intern Med; 2017 Nov; 177(11):1605-1612. PubMed ID: 28975211
[TBL] [Abstract][Full Text] [Related]
6. Reduction of methotrexate and glucocorticoids use after the introduction of biological disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis in daily practice based on the IORRA cohort.
Shimizu Y; Tanaka E; Inoue E; Shidara K; Sugimoto N; Seto Y; Nakajima A; Momohara S; Taniguchi A; Yamanaka H
Mod Rheumatol; 2018 May; 28(3):461-467. PubMed ID: 28880684
[TBL] [Abstract][Full Text] [Related]
7. [Primary central nervous system methotrexate associated lymphoproliferative disorders in a patient with rheumatoid arthritis].
Uchida Y; Hokkoku K; Hatanaka Y; Kikuchi Y; Tashiro H; Sonoo M
Rinsho Shinkeigaku; 2018 Aug; 58(8):485-491. PubMed ID: 30068810
[TBL] [Abstract][Full Text] [Related]
8. Pharmacoeconomic analysis of biological disease modifying antirheumatic drugs in patients with rheumatoid arthritis based on real-world data from the IORRA observational cohort study in Japan.
Tanaka E; Inoue E; Yamaguchi R; Shimizu Y; Kobayashi A; Sugimoto N; Hoshi D; Shidara K; Sato E; Seto Y; Nakajima A; Momohara S; Taniguchi A; Yamanaka H
Mod Rheumatol; 2017 Mar; 27(2):227-236. PubMed ID: 27472516
[TBL] [Abstract][Full Text] [Related]
9. Tofacitinib versus tocilizumab in the treatment of biological-naïve or previous biological-failure patients with methotrexate-refractory active rheumatoid arthritis.
Mori S; Urata Y; Yoshitama T; Ueki Y
RMD Open; 2021 May; 7(2):. PubMed ID: 33958440
[TBL] [Abstract][Full Text] [Related]
10. [Survival of bDMARDs in bionaive patients with rheumatoid arthritis: data from a retrospective 12-month follow-up].
Aronova ES; Lukina GV; Glukhova SI; Gridneva GI; Kudryavtseva AV
Ter Arkh; 2020 Jun; 92(5):39-45. PubMed ID: 32598774
[TBL] [Abstract][Full Text] [Related]
11. Clinical aspects in patients with rheumatoid arthritis complicated with lymphoproliferative disorders without regression after methotrexate withdrawal and treatment for arthritis after regression of lymphoproliferative disorders.
Nakano K; Saito K; Nawata A; Hanami K; Kubo S; Miyagawa I; Fujino Y; Nakayamada S; Tanaka Y
Mod Rheumatol; 2021 Jan; 31(1):94-100. PubMed ID: 32159414
[TBL] [Abstract][Full Text] [Related]
12. Primary Central Nervous System Methotrexate-associated Lymphoproliferative Disorder in a Patient with Rheumatoid Arthritis: Case Report and Review of Literature.
Uneda A; Hirashita K; Kanda T; Yunoki M; Yoshino K; Kurozumi K; Date I
NMC Case Rep J; 2020 Jul; 7(3):121-127. PubMed ID: 32695560
[TBL] [Abstract][Full Text] [Related]
13. The usage of biological DMARDs and clinical remission of rheumatoid arthritis in China: a real-world large scale study.
An Y; Liu T; He D; Wu L; Li J; Liu Y; Bi L; Zhou B; Lin C; He L; Liu X; Li X; Yang N; Zhang Z; Song H; Wei W; Liu J; Bi Y; Li Z
Clin Rheumatol; 2017 Jan; 36(1):35-43. PubMed ID: 27709444
[TBL] [Abstract][Full Text] [Related]
14. Tapering of biological antirheumatic drugs in rheumatoid arthritis patients is achievable and cost-effective in daily clinical practice: data from the Brussels UCLouvain RA Cohort.
Dierckx S; Sokolova T; Lauwerys BR; Avramovska A; de Bellefon LM; Toukap AN; Stoenoiu M; Houssiau FA; Durez P
Arthritis Res Ther; 2020 Apr; 22(1):96. PubMed ID: 32345367
[TBL] [Abstract][Full Text] [Related]
15. Use of healthcare resources in a cohort of rheumatoid arthritis patients treated with biological disease-modifying antirheumatic drugs or tofacitinib.
Machado-Alba JE; Machado-Duque ME; Gaviria-Mendoza A; Reyes JM; Gamboa NC
Clin Rheumatol; 2021 Apr; 40(4):1273-1281. PubMed ID: 32997316
[TBL] [Abstract][Full Text] [Related]
16. Risk factors associated with initiation of a biologic disease modifying anti-rheumatic drug in patients with rheumatoid arthritis: A nested case-control study on 34,925 patients.
Park EH; Shin A; Ha YJ; Lee YJ; Lee EB; Song YW; Kang EH
Joint Bone Spine; 2021 Jan; 88(1):105057. PubMed ID: 32711117
[TBL] [Abstract][Full Text] [Related]
17. Successful Treatment of Intracranial Methotrexate-associated Lymphoproliferative Disorder without Epstein-Barr Virus Infection Using Rituximab, Methotrexate, Procarbazine, and Vincristine: A Case Report.
Mizushima M; Ishi Y; Ikeda H; Echizenya I; Otsuka T; Mitsuhashi T; Yamaguchi S; Fujimura M
NMC Case Rep J; 2022; 9():237-242. PubMed ID: 36061907
[TBL] [Abstract][Full Text] [Related]
18. Use of biological disease modifying antirheumatic drugs in rheumatoid arthritis in Austria from 2008 to 2011 : A retrospective analysis of 72% of the population.
Stamm TA; Reichardt B; Zwerina J; Ritschl V; Nell-Duxneuner V
Wien Klin Wochenschr; 2018 Apr; 130(7-8):230-237. PubMed ID: 29445863
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness of TOcilizumab in comparison to Prednisone In Rheumatoid Arthritis patients with insufficient response to disease-modifying antirheumatic drugs (TOPIRA): study protocol for a pragmatic trial.
van der Leeuw MS; Welsing PMJ; de Hair MJH; Jacobs JWG; Marijnissen ACA; Linn-Rasker SP; Fodili F; Bos R; Tekstra J; van Laar JM
Trials; 2020 Apr; 21(1):313. PubMed ID: 32248829
[TBL] [Abstract][Full Text] [Related]
20. Outcomes of methotrexate-associated lymphoproliferative disorders in rheumatoid arthritis patients treated with disease-modifying anti-rheumatic drugs.
Harada T; Iwasaki H; Muta T; Urata S; Sakamoto A; Kohno K; Takase K; Miyamura T; Sawabe T; Asaoku H; Oryoji K; Fujisaki T; Mori Y; Yoshimoto G; Ayano M; Mitoma H; Miyamoto T; Niiro H; Yamamoto H; Oshiro Y; Miyoshi H; Ohshima K; Takeshita M; Akashi K; Kato K
Br J Haematol; 2021 Jul; 194(1):101-110. PubMed ID: 33822354
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
